Annual Total Liabilities
$356.16 M
-$460.15 M-56.37%
December 31, 2023
Summary
- As of February 12, 2025, SUPN annual total liabilities is $356.16 million, with the most recent change of -$460.15 million (-56.37%) on December 31, 2023.
- During the last 3 years, SUPN annual total liabilities has fallen by -$403.09 million (-53.09%).
- SUPN annual total liabilities is now -59.22% below its all-time high of $873.30 million, reached on December 31, 2021.
Performance
SUPN Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$335.55 M
-$22.82 M-6.37%
September 30, 2024
Summary
- As of February 12, 2025, SUPN quarterly total liabilities is $335.55 million, with the most recent change of -$22.82 million (-6.37%) on September 30, 2024.
- Over the past year, SUPN quarterly total liabilities has dropped by -$37.42 million (-10.03%).
- SUPN quarterly total liabilities is now -61.85% below its all-time high of $879.66 million, reached on March 31, 2023.
Performance
SUPN Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
SUPN Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -56.4% | -10.0% |
| 3 y3 years | -53.1% | -10.0% |
| 5 y5 years | -32.1% | -10.0% |
SUPN Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -59.2% | at low | -61.9% | at low |
| 5 y | 5-year | -59.2% | at low | -61.9% | at low |
| alltime | all time | -59.2% | +877.9% | -61.9% | +821.4% |
Supernus Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $335.55 M(-6.4%) |
| Jun 2024 | - | $358.38 M(-4.4%) |
| Mar 2024 | - | $374.92 M(+5.3%) |
| Dec 2023 | $356.16 M(-56.4%) | $356.16 M(-4.5%) |
| Sep 2023 | - | $372.97 M(-0.1%) |
| Jun 2023 | - | $373.19 M(-57.6%) |
| Mar 2023 | - | $879.66 M(+7.8%) |
| Dec 2022 | $816.30 M(-6.5%) | $816.30 M(-2.9%) |
| Sep 2022 | - | $840.33 M(-1.5%) |
| Jun 2022 | - | $853.54 M(+5.2%) |
| Mar 2022 | - | $811.07 M(-7.1%) |
| Dec 2021 | $873.30 M(+15.0%) | $873.30 M(+17.3%) |
| Sep 2021 | - | $744.57 M(-5.4%) |
| Jun 2021 | - | $787.48 M(+4.6%) |
| Mar 2021 | - | $753.00 M(-0.8%) |
| Dec 2020 | $759.24 M(+34.4%) | $759.24 M(-5.2%) |
| Sep 2020 | - | $801.14 M(-2.9%) |
| Jun 2020 | - | $825.05 M(+43.1%) |
| Mar 2020 | - | $576.48 M(+2.1%) |
| Dec 2019 | $564.85 M(+7.6%) | $564.85 M(+2.8%) |
| Sep 2019 | - | $549.65 M(+1.6%) |
| Jun 2019 | - | $540.77 M(-0.9%) |
| Mar 2019 | - | $545.43 M(+3.9%) |
| Dec 2018 | $524.79 M(+234.3%) | $524.79 M(+4.8%) |
| Sep 2018 | - | $500.58 M(+8.3%) |
| Jun 2018 | - | $462.31 M(-2.3%) |
| Mar 2018 | - | $473.29 M(+201.5%) |
| Dec 2017 | $156.98 M | $156.98 M(+17.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $133.81 M(+14.4%) |
| Jun 2017 | - | $116.97 M(+0.7%) |
| Mar 2017 | - | $116.19 M(-1.4%) |
| Dec 2016 | $117.81 M(+17.1%) | $117.81 M(+5.4%) |
| Sep 2016 | - | $111.75 M(+44.0%) |
| Jun 2016 | - | $77.61 M(+17.0%) |
| Mar 2016 | - | $66.33 M(-34.1%) |
| Dec 2015 | $100.62 M(+4.7%) | $100.62 M(+75.5%) |
| Sep 2015 | - | $57.33 M(+10.7%) |
| Jun 2015 | - | $51.80 M(+15.0%) |
| Mar 2015 | - | $45.05 M(-53.1%) |
| Dec 2014 | $96.08 M(+23.9%) | $96.08 M(+59.6%) |
| Sep 2014 | - | $60.21 M(-1.0%) |
| Jun 2014 | - | $60.82 M(-11.2%) |
| Mar 2014 | - | $68.51 M(-11.6%) |
| Dec 2013 | $77.53 M(+112.9%) | $77.53 M(-30.3%) |
| Sep 2013 | - | $111.31 M(+15.9%) |
| Jun 2013 | - | $96.08 M(+154.3%) |
| Mar 2013 | - | $37.79 M(+3.8%) |
| Dec 2012 | $36.42 M(-17.8%) | $36.42 M(-14.1%) |
| Sep 2012 | - | $42.38 M(+0.9%) |
| Jun 2012 | - | $41.98 M(-2.2%) |
| Mar 2012 | - | $42.93 M(-3.1%) |
| Dec 2011 | $44.29 M(-51.5%) | $44.29 M(-57.8%) |
| Sep 2011 | - | $104.83 M(+14.8%) |
| Dec 2010 | $91.33 M(+6.1%) | $91.33 M(-2.2%) |
| Sep 2010 | - | $93.42 M(+8.6%) |
| Dec 2009 | $86.06 M(+2.6%) | $86.06 M |
| Dec 2008 | $83.88 M | - |
FAQ
- What is Supernus Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual total liabilities year-on-year change?
- What is Supernus Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly total liabilities year-on-year change?
What is Supernus Pharmaceuticals annual total liabilities?
The current annual total liabilities of SUPN is $356.16 M
What is the all time high annual total liabilities for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual total liabilities is $873.30 M
What is Supernus Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, SUPN annual total liabilities has changed by -$460.15 M (-56.37%)
What is Supernus Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of SUPN is $335.55 M
What is the all time high quarterly total liabilities for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly total liabilities is $879.66 M
What is Supernus Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, SUPN quarterly total liabilities has changed by -$37.42 M (-10.03%)